Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Janumet vs Metformin in Type 2 Diabetes Mellitus
NCT00482729Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Hemoglobin A1c at 18 weeks. Started Jun 2007; status: completed.
02
Drugs
sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00482729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482729.